News

The Phase 3 study, which enrolled 2,838 adults, age 18-45 years, met both the primary and secondary endpoints. “We are thrilled with the results of the CONSTANT study,

Under the three-year collaboration, Empirico will use its Precision Insights Platform to determine therapeutic targets for indications and tissues, which are responsive to antisense technology. The Precision Insights

This exploratory Phase 2 trial, which is subject to the receipt of adequate funding, is designed to assess safety, pharmacokinetics and exploratory measures of function including cardiac, skeletal

The technology is expected to be capable of enumerating, screening, and scoring billions of synthetically feasible, virtual compounds supporting the identification and optimization of potential new therapeutic candidates.

Keytruda has been approved to treat patients with BCG- unresponsive, high-risk NMIBC with carcinoma in situ (CIS) with or without papillary tumours who are ineligible for or have

SM-88 is one of the cancer metabolism-based therapies (CMBTs) that are being developed by Tyme Technologies. According to the company, CMBTs are investigational compounds that can potentially disrupt

The collaborations will explore the possibility and the potential of new therapies to treat challenging autoimmune, infectious and idiopathic diseases by leveraging SAB’s DiversitAb platform. SAB has developed

The European Medicines Agency’s (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. “The EMA’s validation of Incyte’s Marketing

Reported to be the world’s largest independent funder of cancer research, Cancer Research UK will provide funding for the exploratory development of Bicycle’s BT7401 candidate through a phase